Good morning,
the latest report from GlobalPETS shows that we are not cutting back on the health and wellbeing of our pets. Supplements, functional diets and innovative veterinary treatments are generating growing demand worldwide. Biological therapies for companion animals are very much our specialty. And dogs? They may soon see a breakthrough drug for osteoarthritis!
*Save the date / We will discuss individual projects, including correspondence with the European Medicines Agency, the full results of the BCX-CM-AD clinical trial for atopic dermatitis, and progress related to the new manufacturing facility during an August webinar with the participation of the Bioceltix Management Board. The exact date will be announced soon. It will depend on the schedule of information received from the EMA and on the pace at which we process the complete set of data from the clinical trial for atopic dermatitis in dogs*
In the meantime, we invite you to a newsletter overview of recent events in the Company’s life:
- At the European Medicines Agency, the substantive assessment of Bioceltix’s second product is underway: BCX-EM for arthritis in horses has joined BCX-CM-J for osteoarthritis in dogs. This means that our cooperation with the market regulator now covers two parallel registration processes. If everything goes according to plan, commercialization of Bioceltix’s first product will take place at the end of 2026. We can also put it this way: we have a chance to become the first company in the world with a medicinal product containing canine stem cells approved for marketing. At the same time, we would like to remind you that the preliminary results of the BCX-CM-AD clinical trial for atopic dermatitis in dogs confirmed its effectiveness in the short, medium and long term from the moment of administration. We are currently awaiting the final, complete results of the clinical trial. We are proving that it is possible to effectively, safely and long-term treat an inflammatory and autoimmune disease in dogs using intravenously administered stem cells. | Read more
- We have signed an agreement with PARP for co-financing of the project “Construction and launch of a pharmaceutical manufacturing facility for innovative advanced therapy veterinary medicinal products” under the European Funds for a Modern Economy programme. The total cost of project implementation amounts to PLN 60.98 million, the total eligible expenditure to PLN 49.58 million, and the total amount of co-financing for the project to PLN 17.35 million. The terms and conditions of the agreement are described in detail in a current report. | Read more
- Four-legged patients are waiting for a breakthrough, just like the entire Polish biotechnology sector. We believe that a successful registration process for our products will pave the way for further innovations from Poland. Does domestic biotech have a chance for a place on the global podium? Paweł Wielgus spoke about the condition of the sector in a recent interview for Rzeczpospolita and Parkiet. “Without structural changes at the foundations, primarily covering the way innovative ventures are financed, it is difficult to expect that discoveries ‘made in Poland’ will break through university walls on a scale matching Western standards.” | Read more
- Correspondence from WallStreet. During the Carpathian investor event, Paweł Wielgus, in a conversation with Telewizja Biznesowa, talked about our path from idea to commercialization, as well as insights brought back from recent international conferences, such as Animal Health, Nutrition and Technology Innovation in Boston. The interview is available here.
What’s new in veterinary medicine and biotechnology, in Poland and worldwide?
- According to the newly published GlobalPETS report “2025 Trends: What can we expect from pet consumers and how will the industry evolve?”, the global pet products market will grow from USD 320 billion to USD 500 billion by 2030. Dynamic growth is driven by caretakers’ concern for pet health, a focus on premium products and therapies, and, as a result, higher quality and longer lives for animals. According to the authors of the publication, some of the fastest-growing segments include products supporting the digestive system and joint health. Demand is also increasing for supplements used to improve mobility, alleviate allergies and even reduce anxiety in our four-legged companions. | Read more
- Among those following these trends are the British. The Animalcare Group has announced a strategic partnership with Belgian biotech company YUN, specializing in probiotics. The cooperation will cover the development and commercialization of microbiome-based veterinary products. For Animalcare, this strengthens its position as a leader in veterinary innovation. The British-Belgian alliance is also a signal that the industry is increasingly moving away from traditional pharmacological therapies towards precision treatment methods based on microflora, immunomodulation or bioengineering. Let us recall that last year Animalcare acquired the Australian company Randlab, offering veterinary products for horses. The value of this transaction amounted to approximately PLN 320 million. | Read more
- A bioprinted patch imitating skin and applied to the wounds of companion animals is another interesting step toward the development of veterinary biotechnology. Scientists from the Vilnius-based startup Vital3D have developed a laser system that allows for precise placement of living cells and biomaterials in three-dimensional structures. The surface of the printed patch is covered with micropores with a width of one-fifth of a human hair. They enable air circulation and block bacteria, ultimately shortening treatment time and reducing the risk of infection. The authors of this solution claim that in the future it will be possible to produce—or rather bioprint—entire organs. | Read more
- We are also watching progress in the development of a Central European network of veterinary clinics at LuxVet. The company has raised several dozen million euros for acquisitions in Poland and the CEE region. The market consolidator’s revenues already exceed PLN 200 million. Plans for further acquisitions and investments show that veterinary services are popular not only among pet owners, but also among investors seeking market opportunities. We observe that the fragmented veterinary care market is becoming more professional in order to catch up with Western European standards of work and patient care. | Read more
- We know very well that holiday trips often mean a difficult separation from a pet. How do pet hotels operate in Poland? How can you check such a place? What is worth knowing before signing a contract and what should it include? Useful tips for pet caretakers via infowet.pl.
PS Anyone ordered some WimbleDogs content? >Click< 🐶🎾☺️
We publish even more industry news and up-to-date information on the progress of our work on LinkedIn – we invite you to follow the Bioceltix profile.
If you have suggestions regarding the newsletter content, please contact us at: newsletter@bioceltix.com.
With holiday greetings,
The Bioceltix Team